GB901107A - Therapeutic composition and method of preparing same - Google Patents
Therapeutic composition and method of preparing sameInfo
- Publication number
- GB901107A GB901107A GB2228959A GB2228959A GB901107A GB 901107 A GB901107 A GB 901107A GB 2228959 A GB2228959 A GB 2228959A GB 2228959 A GB2228959 A GB 2228959A GB 901107 A GB901107 A GB 901107A
- Authority
- GB
- United Kingdom
- Prior art keywords
- sodium
- magnesium
- oxytetracycline
- tetracycline
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 239000000243 solution Substances 0.000 abstract 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- 239000004098 Tetracycline Substances 0.000 abstract 3
- 229910052791 calcium Inorganic materials 0.000 abstract 3
- 239000011575 calcium Substances 0.000 abstract 3
- 229910052749 magnesium Inorganic materials 0.000 abstract 3
- 239000011777 magnesium Substances 0.000 abstract 3
- 229910052751 metal Inorganic materials 0.000 abstract 3
- 239000002184 metal Substances 0.000 abstract 3
- 229920001223 polyethylene glycol Polymers 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 229960002180 tetracycline Drugs 0.000 abstract 3
- 235000019364 tetracycline Nutrition 0.000 abstract 3
- 229930101283 tetracycline Natural products 0.000 abstract 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 2
- 239000004100 Oxytetracycline Substances 0.000 abstract 2
- 239000004411 aluminium Substances 0.000 abstract 2
- 229910052782 aluminium Inorganic materials 0.000 abstract 2
- -1 aluminium tetracycline salt Chemical class 0.000 abstract 2
- 230000003115 biocidal effect Effects 0.000 abstract 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 abstract 2
- 229960000625 oxytetracycline Drugs 0.000 abstract 2
- 235000019366 oxytetracycline Nutrition 0.000 abstract 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 abstract 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 abstract 2
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 abstract 2
- 150000003522 tetracyclines Chemical class 0.000 abstract 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 abstract 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 abstract 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 abstract 1
- YCPXWRQRBFJBPZ-UHFFFAOYSA-N 5-sulfosalicylic acid Chemical compound OC(=O)C1=CC(S(O)(=O)=O)=CC=C1O YCPXWRQRBFJBPZ-UHFFFAOYSA-N 0.000 abstract 1
- 229930188120 Carbomycin Natural products 0.000 abstract 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 abstract 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 abstract 1
- 239000004150 EU approved colour Substances 0.000 abstract 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 abstract 1
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 abstract 1
- 239000004104 Oleandomycin Substances 0.000 abstract 1
- RZPAKFUAFGMUPI-UHFFFAOYSA-N Oleandomycin Natural products O1C(C)C(O)C(OC)CC1OC1C(C)C(=O)OC(C)C(C)C(O)C(C)C(=O)C2(OC2)CC(C)C(OC2C(C(CC(C)O2)N(C)C)O)C1C RZPAKFUAFGMUPI-UHFFFAOYSA-N 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 abstract 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 abstract 1
- FQVHOULQCKDUCY-OGHXVOSASA-N [(2s,3s,4r,6s)-6-[(2r,3s,4r,5r,6s)-6-[[(1s,3r,7r,8s,9s,10r,12r,14e,16s)-7-acetyloxy-8-methoxy-3,12-dimethyl-5,13-dioxo-10-(2-oxoethyl)-4,17-dioxabicyclo[14.1.0]heptadec-14-en-9-yl]oxy]-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2,4-dimeth Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@H]1[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/[C@@H]2O[C@H]2C[C@@H](C)OC(=O)C[C@H]([C@@H]1OC)OC(C)=O)[C@H]1C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O1 FQVHOULQCKDUCY-OGHXVOSASA-N 0.000 abstract 1
- PGTXKIZLOWULDJ-UHFFFAOYSA-N [Mg].[Zn] Chemical compound [Mg].[Zn] PGTXKIZLOWULDJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000005456 alcohol based solvent Substances 0.000 abstract 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 239000011668 ascorbic acid Substances 0.000 abstract 1
- 229960005070 ascorbic acid Drugs 0.000 abstract 1
- 239000006172 buffering agent Substances 0.000 abstract 1
- 229950005779 carbomycin Drugs 0.000 abstract 1
- 238000004040 coloring Methods 0.000 abstract 1
- 229960004544 cortisone Drugs 0.000 abstract 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 abstract 1
- 239000000645 desinfectant Substances 0.000 abstract 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000013355 food flavoring agent Nutrition 0.000 abstract 1
- ISXSFOPKZQZDAO-UHFFFAOYSA-N formaldehyde;sodium Chemical compound [Na].O=C ISXSFOPKZQZDAO-UHFFFAOYSA-N 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- 229940041616 menthol Drugs 0.000 abstract 1
- 150000002739 metals Chemical class 0.000 abstract 1
- 239000002324 mouth wash Substances 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 239000002674 ointment Substances 0.000 abstract 1
- RZPAKFUAFGMUPI-KGIGTXTPSA-N oleandomycin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C RZPAKFUAFGMUPI-KGIGTXTPSA-N 0.000 abstract 1
- 235000019367 oleandomycin Nutrition 0.000 abstract 1
- 229960002351 oleandomycin Drugs 0.000 abstract 1
- 229960005205 prednisolone Drugs 0.000 abstract 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 abstract 1
- 229940081974 saccharin Drugs 0.000 abstract 1
- 235000019204 saccharin Nutrition 0.000 abstract 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 abstract 1
- 235000010378 sodium ascorbate Nutrition 0.000 abstract 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 abstract 1
- 229960005055 sodium ascorbate Drugs 0.000 abstract 1
- 229960001462 sodium cyclamate Drugs 0.000 abstract 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 abstract 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 abstract 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 239000003270 steroid hormone Substances 0.000 abstract 1
- 229960005322 streptomycin Drugs 0.000 abstract 1
- 239000000829 suppository Substances 0.000 abstract 1
- NCPXQVVMIXIKTN-UHFFFAOYSA-N trisodium;phosphite Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])[O-] NCPXQVVMIXIKTN-UHFFFAOYSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A therapeutic composition comprises a solution of at least one of the following antibiotic salts: magnesium, calcium or aluminium tetracycline salt or a magnesium, calcium aluminium or zinc oxytetracycline salt in one or more of the following polyhydric aliphatic alcohol solvents: glycerine, polyethylene glycol or propylene glycol, the molar ratio of metal to antibiotic being about 3 : 1 in the case of tetracycline and from 1 : 3 to 3 : 1 in the case of oxytetracycline and the pH of the solution being from 7 to 10. The metal tetracycline or oxtetracycline salts may be prepared in situ and mixed salts of two metals may be employed e.g. calcium, magnesium oxytetracycline or magnesium zinc oxtetracycline. A non-toxic alkanol, e.g. sorbitol or ethanol may be added in an amount of up to 20% of the solutions. The compositions are administered (a) intramuscularly or when diluted with water intravenously, (b) as otic or veterinary opthalmic solutions and in humans as otic solutions, mouthwashes or disinfectants, or (c) as salves or suppositories, using as a solvent a high molecular weight polyethylene glycol, e.g. the carbowaxes. The compositions may contain additionally (a) antibiotics, e.g. streptomycin, polymixin B sulphate, carbomycin or oleandomycin, (b) steroid hormones, e.g. prednisolone, cortisone or hydrocortisone, (c) buffering agents and other stabilizers, e.g. ascorbic acid, triethanolamine, diethanolamine, sodium phosphite, sodium bisulphite and sodium formaldehyde sulphorylate, (d) colouring and flavouring agents, e.g. sodium cyclamate, sodium saccharin, sodium ascorbate, menthol, sodium sucaryl, saccharin, sulphosalicylic acid and benzocain.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2228959A GB901107A (en) | 1959-06-29 | 1959-06-29 | Therapeutic composition and method of preparing same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2228959A GB901107A (en) | 1959-06-29 | 1959-06-29 | Therapeutic composition and method of preparing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB901107A true GB901107A (en) | 1962-07-11 |
Family
ID=10176976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB2228959A Expired GB901107A (en) | 1959-06-29 | 1959-06-29 | Therapeutic composition and method of preparing same |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB901107A (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE40086E1 (en) | 1991-10-04 | 2008-02-19 | Wyeth Holdings Corporation | Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines |
| USRE40183E1 (en) | 1991-10-04 | 2008-03-25 | Wyeth Holdings Corporation | 7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines |
| WO2008118744A1 (en) * | 2007-03-23 | 2008-10-02 | Molecular Research Center, Inc. | Anti-inflammatory compositions comprising tetracyclines and use thereof in therapy |
| WO2010114680A1 (en) | 2009-03-12 | 2010-10-07 | Wyeth Llc | Nitration of tetracyclines |
| US7879828B2 (en) | 2005-03-14 | 2011-02-01 | Wyeth Llc | Tigecycline compositions and methods of preparation |
| US8357696B2 (en) | 2005-05-18 | 2013-01-22 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| AU2012230089B2 (en) * | 2007-03-23 | 2013-11-21 | Molecular Research Center, Inc. | Anti-inflammatory compositions comprising tetracyclines and use thereof in therapy |
| US8629139B2 (en) | 2008-10-07 | 2014-01-14 | Mpex Pharmaceuticals, Inc. | Topical use of Levofloxacin for reducing lung inflammation |
| US8815838B2 (en) | 2008-10-07 | 2014-08-26 | David C. Griffith | Aerosol fluoroquinolone formulations for improved pharmacokinetics |
| US20150094282A1 (en) * | 2010-05-12 | 2015-04-02 | Rempex Pharmaceuticals, Inc. | Tetracycline compositions |
| WO2016154232A3 (en) * | 2015-03-23 | 2016-12-08 | BioPharmX, Inc. | Pharmaceutical tetracycline composition for dermatological use |
| US9700564B2 (en) | 2009-09-04 | 2017-07-11 | Horizon Orphan Llc | Use of aerosolized levofloxacin for treating cystic fibrosis |
-
1959
- 1959-06-29 GB GB2228959A patent/GB901107A/en not_active Expired
Cited By (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE40183E1 (en) | 1991-10-04 | 2008-03-25 | Wyeth Holdings Corporation | 7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines |
| USRE40086E1 (en) | 1991-10-04 | 2008-02-19 | Wyeth Holdings Corporation | Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines |
| US9254328B2 (en) | 2005-03-14 | 2016-02-09 | Wyeth Llc | Tigecycline compositions and methods of preparation |
| US8975242B2 (en) | 2005-03-14 | 2015-03-10 | Wyeth Llc | Tigecycline compositions and methods of preparation |
| US9694078B2 (en) | 2005-03-14 | 2017-07-04 | Wyeth Llc | Tigecycline compositions and methods of preparation |
| US7879828B2 (en) | 2005-03-14 | 2011-02-01 | Wyeth Llc | Tigecycline compositions and methods of preparation |
| US10588975B2 (en) | 2005-03-14 | 2020-03-17 | Wyeth Llc | Tigecycline compositions and methods of preparation |
| US8357696B2 (en) | 2005-05-18 | 2013-01-22 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| US8524734B2 (en) | 2005-05-18 | 2013-09-03 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| US8524735B2 (en) | 2005-05-18 | 2013-09-03 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| US8546423B2 (en) | 2005-05-18 | 2013-10-01 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| US10987357B2 (en) | 2005-05-18 | 2021-04-27 | Horizon Orphan, LLC | Aerosolized fluoroquinolones and uses thereof |
| AU2008231033B2 (en) * | 2007-03-23 | 2012-08-30 | Molecular Research Center, Inc. | Anti-inflammatory compositions comprising tetracyclines and use thereof in therapy |
| AU2012230089B2 (en) * | 2007-03-23 | 2013-11-21 | Molecular Research Center, Inc. | Anti-inflammatory compositions comprising tetracyclines and use thereof in therapy |
| EA016206B1 (en) * | 2007-03-23 | 2012-03-30 | Моликьюлар Рисерч Сентер, Инк. | Composition and method for treating anti-inflammatory disorders |
| JP2010522240A (en) * | 2007-03-23 | 2010-07-01 | モレキュラー リサーチ センター インコーポレイテッド | Compositions and methods for treating inflammation |
| WO2008118744A1 (en) * | 2007-03-23 | 2008-10-02 | Molecular Research Center, Inc. | Anti-inflammatory compositions comprising tetracyclines and use thereof in therapy |
| US9326936B2 (en) | 2008-10-07 | 2016-05-03 | Raptor Pharmaceuticals, Inc. | Aerosol fluoroquinolone formulations for improved pharmacokinetics |
| US10149854B2 (en) | 2008-10-07 | 2018-12-11 | Horizon Orphan Llc | Aerosol fluoroquinolone formulations for improved pharmacokinetics |
| US11020481B2 (en) | 2008-10-07 | 2021-06-01 | Horizon Orphan Llc | Topical use of levofloxacin for reducing lung inflammation |
| US10722519B2 (en) | 2008-10-07 | 2020-07-28 | Horizon Orphan Llc | Aerosol fluoroquinolone formulations for improved pharmacokinetics |
| US8815838B2 (en) | 2008-10-07 | 2014-08-26 | David C. Griffith | Aerosol fluoroquinolone formulations for improved pharmacokinetics |
| US8629139B2 (en) | 2008-10-07 | 2014-01-14 | Mpex Pharmaceuticals, Inc. | Topical use of Levofloxacin for reducing lung inflammation |
| US9717738B2 (en) | 2008-10-07 | 2017-08-01 | Horizon Orphan Llc | Aerosol fluoroquinolone formulations for improved pharmacokinetics |
| WO2010114680A1 (en) | 2009-03-12 | 2010-10-07 | Wyeth Llc | Nitration of tetracyclines |
| US9700564B2 (en) | 2009-09-04 | 2017-07-11 | Horizon Orphan Llc | Use of aerosolized levofloxacin for treating cystic fibrosis |
| US10231975B2 (en) | 2009-09-04 | 2019-03-19 | Horizon Orphan Llc | Use of aerosolized levofloxacin for treating cystic fibrosis |
| US10792289B2 (en) | 2009-09-04 | 2020-10-06 | Horizon Orphan Llc | Use of aerosolized levofloxacin for treating cystic fibrosis |
| US20150094282A1 (en) * | 2010-05-12 | 2015-04-02 | Rempex Pharmaceuticals, Inc. | Tetracycline compositions |
| US12161656B2 (en) | 2010-05-12 | 2024-12-10 | Melinta Subsidiary Corp. | Tetracycline compositions |
| US9744179B2 (en) | 2010-05-12 | 2017-08-29 | Rempex Pharmaceuticals, Inc. | Tetracycline compositions |
| US11944634B2 (en) | 2010-05-12 | 2024-04-02 | Melinta Subsidiary Corp. | Tetracycline compositions |
| US9084802B2 (en) | 2010-05-12 | 2015-07-21 | Rempex Pharmaceuticals, Inc. | Tetracycline compositions |
| US9278105B2 (en) | 2010-05-12 | 2016-03-08 | Rempex Pharmaceuticals, Inc. | Tetracycline compositions |
| WO2016154232A3 (en) * | 2015-03-23 | 2016-12-08 | BioPharmX, Inc. | Pharmaceutical tetracycline composition for dermatological use |
| AU2016235237B2 (en) * | 2015-03-23 | 2021-03-11 | BioPharmX, Inc. | Pharmaceutical tetracycline composition for dermatological use |
| US10881672B2 (en) | 2015-03-23 | 2021-01-05 | BioPharmX, Inc. | Pharmaceutical tetracycline composition for dermatological use |
| CN107708665A (en) * | 2015-03-23 | 2018-02-16 | 贝尔生物制药有限公司 | Medicinal Fourth Ring promotor composition for dermatological use |
| CN107708665B (en) * | 2015-03-23 | 2022-07-22 | 贝尔生物制药有限公司 | Pharmaceutical tetracycline compositions for dermatological use |
| US10391108B2 (en) | 2015-03-23 | 2019-08-27 | BioPharmX, Inc. | Pharmaceutical tetracycline composition for dermatological use |
| US9918998B2 (en) | 2015-03-23 | 2018-03-20 | BioPharmX, Inc. | Pharmaceutical tetracycline composition for dermatological use |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB901107A (en) | Therapeutic composition and method of preparing same | |
| GB1059188A (en) | Colour stable oxytetracycline compositions and process for preparing same | |
| DE2817335A1 (en) | ANTIBIOTIC TETRACYCLINE CONTAINERS | |
| GB1252207A (en) | ||
| GB1471099A (en) | Topical composition | |
| GB1038678A (en) | Compounds having an adrenocorticotrophic hormone action and process for their manufacture | |
| ES431601A1 (en) | Stable prostaglandin E group-containing formulation | |
| GB1245467A (en) | Slow release antibiotic composition | |
| ES400927A1 (en) | Dentrifrices | |
| GB1150561A (en) | Coating Compositions for High Grade Paper | |
| GB1336164A (en) | Hydrophilic film-forming colloid composition | |
| ES450897A1 (en) | N-Tetrahydrofurfuryl-noroxymorphones, their salts, and analgesic compositions and methods employing them | |
| ES415719A1 (en) | Method of preparation of complex compounds of aminodicarboxilic acids. (Machine-translation by Google Translate, not legally binding) | |
| ES423349A1 (en) | Stable solutions of calcium salts | |
| GB578540A (en) | Improvements in and relating to polyethylene glycol compositions | |
| GB1074491A (en) | Novel processes for preparing steroid compounds, the compounds when thus prepared, novel steroid compounds thereby prepared, and pharmaceutical compositions containing the novel compounds | |
| GB1276589A (en) | 0-alkyl-6-azauracil compounds and compositions containing the same | |
| GB1434757A (en) | Method and composition for the control of fertility | |
| GB1463550A (en) | Pharmaceutical composition | |
| GB1348258A (en) | 9-oxo-6.9-dihydro-4h-dioxino-4,5-g-quinolyl-8-carboxylic acids and their isomers, 10-oxo-7,10-dihydro-1h-dioxino-5,4-f-quinolyl- 9-carboxylic acids | |
| GB923942A (en) | New compounds, processes for preparing them and pharmaceutical compositions containing them | |
| ES350802A1 (en) | Benzylisoquinolinic solutions and method of making the same | |
| GB1319402A (en) | 3-acyloxypropyl-2,-trimethylammoniumethyl phosphates | |
| Izumi | Studies on Cancerocidal Substances. XII. Reaction of N-Bis (β-chloroethyl) amino Acids and their N-Oxides in an Aqueous Solution | |
| GB814866A (en) | Make-up removing compositions |